Pivotal bioVenture Partners Investment Advisor’s Vaxcyte PCVX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79.8M	Hold	1,372,425	–	–	28.51%	1
2025 Q4	$63.3M	Hold	1,372,425	–	–	24.48%	1
2025 Q3	$49.4M	Buy	1,372,425 +67,300	+5%	+$2.23M	28.58%	1
2025 Q2	$42.4M	Buy	1,305,125 +594,391	+84%	+$19.5M	26.3%	2
2025 Q1	$26.8M	Buy	710,734 +6,900	+1%	+$552K	21.72%	3
2024 Q4	$57.6M	Buy	703,834 +64,295	+10%	+$6.38M	38.91%	1
2024 Q3	$73.1M	Sell	639,539 -153,497	-19%	-$13.8M	43.38%	1
2024 Q2	$59.9M	Hold	793,036	–	–	46.04%	1
2024 Q1	$54.2M	Hold	793,036	–	–	34.82%	1
2023 Q4	$49.8M	Hold	793,036	–	–	12.63%	2
2023 Q3	$40.4M	Hold	793,036	–	–	16.13%	2
2023 Q2	$39.6M	Buy	793,036 +99,997	+14%	+$4.74M	13.06%	2
2023 Q1	$26M	Hold	693,039	–	–	10.7%	2
2022 Q4	$33.2M	Sell	693,039 -83,000	-11%	-$3.26M	14.45%	2
2022 Q3	$18.6M	Sell	776,039 -56,127	-7%	-$1.42M	6.81%	3
2022 Q2	$18.1M	Sell	832,166 -279,319	-25%	-$6.46M	9.12%	2
2022 Q1	$26.8M	Hold	1,111,485	–	–	12.7%	2
2021 Q4	$26.4M	Sell	1,111,485 -293,936	-21%	-$6.84M	11.06%	2
2021 Q3	$35.7M	Hold	1,405,421	–	–	12.6%	3
2021 Q2	$31.6M	Hold	1,405,421	–	–	12.47%	2
2021 Q1	$27.8M	Sell	1,405,421 -817,549	-37%	-$20.6M	8.91%	4
2020 Q4	$59.1M	Buy	+2,222,970	New	+$82.6M	19.47%	2

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's PCVX Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Vaxcyte (PCVX) position steady in Q1 2026 at 1,372,425 shares worth $79.8M. The position accounts for 28.51% of the portfolio, ranked #1.

Pivotal bioVenture Partners Investment Advisor first reported a position in PCVX in Q4 2020 and has held it in 22 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Pivotal bioVenture Partners Investment Advisor held 1,372,425 shares of Vaxcyte worth $79.8M as of Q1 2026.
Pivotal bioVenture Partners Investment Advisor left its Vaxcyte share count unchanged in Q1 2026.
Vaxcyte made up 28.51% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #1 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Vaxcyte in Q4 2020 and has held it in 22 quarters since.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.